Pfizer Inc. (NYSE:PFE) Shares Bought by B.O.S.S. Retirement Advisors LLC

B.O.S.S. Retirement Advisors LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 85,052 shares of the biopharmaceutical company’s stock after acquiring an additional 11,558 shares during the quarter. B.O.S.S. Retirement Advisors LLC’s holdings in Pfizer were worth $2,461,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Wolff Wiese Magana LLC increased its stake in shares of Pfizer by 108.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 3,342 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 1,741 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in shares of Pfizer by 10.3% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 256,460 shares of the biopharmaceutical company’s stock worth $7,422,000 after purchasing an additional 23,928 shares during the period. Vontobel Holding Ltd. grew its holdings in shares of Pfizer by 11.5% during the 3rd quarter. Vontobel Holding Ltd. now owns 551,708 shares of the biopharmaceutical company’s stock worth $15,966,000 after purchasing an additional 57,013 shares during the period. Sumitomo Life Insurance Co. grew its holdings in shares of Pfizer by 2.5% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 53,470 shares of the biopharmaceutical company’s stock worth $1,547,000 after purchasing an additional 1,305 shares during the period. Finally, SeaCrest Wealth Management LLC grew its holdings in shares of Pfizer by 6.3% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 72,295 shares of the biopharmaceutical company’s stock worth $2,092,000 after purchasing an additional 4,262 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $29.66 on Thursday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The stock has a market cap of $168.07 billion, a P/E ratio of -494.33, a price-to-earnings-growth ratio of 1.30 and a beta of 0.67. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $33.19. The stock has a 50 day moving average of $29.04 and a 200-day moving average of $28.42.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.67 EPS. On average, analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.66%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently -2,800.00%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PFE. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Thursday, October 3rd. Barclays boosted their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, UBS Group upped their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Six analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.10.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.